WD重复域5 (WDR5) 抑制剂:专利审查 (2016年至今)
Jesse A Coker1,2, Shaun R Stauffer1,2
1Center for Therapeutics Discovery, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Expert opinion on therapeutic patents
|December 20, 2024
概括
WDR5蛋白是一种有前途的抗癌点,特别是在白血病中. 这次审查强调了挑战,并建议将WDR5 WIN位点抑制剂推进为白血病治疗的临床试验.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
- 药用化学 医学化学
背景情况:
- WDR5是一种表观遗传支架蛋白,也是抗癌药物的关键标,特别是在MLL重组型白血病中.
- 对于染色质结合至关重要的WDR5 WIN位点,已被强大的小分子抑制剂准.
- 还开发了针对WBM站点的WDR5降解剂和抑制剂.
研究的目的:
- 提供针对WDR5的化学物质的全面概述,重点关注报告不足的专有化合物.
- 识别和解决阻碍WDR5向药物开发的关键挑战.
主要方法:
- 使用SciFinder (2016-2024) 进行的国际专利文献调查.
- 针对WDR5的化学物质的分析,包括WIN-site和WBM-site抑制剂和降解剂.
主要成果:
- 鉴定出缺乏化学多样性和关于WIN位点抑制机制的混乱.
- 注意到脑透性支架的稀缺性和有限的药理动力学/药理动力学数据.
- 观察到WDR5向药物的人类安全性和有效性数据缺乏.
结论:
- 建议将最优秀的WIN位点抑制剂,特别是来自伊米达类的WIN位点抑制剂推进到临床试验中.
- 建议将临床试验重点放在白血病上,WDR5的治疗潜力在这里是最有前途的.
- 强调需要进一步的研究来验证WDR5作为下一代治疗点.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
467
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
467
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
608
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
608
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K


